A revolutionary 60-minute therapy for high blood pressure could allow patients to throw their tablets away for good.
The unlikely remedy involves blasting nerves in the kidneys with sound waves to stop them sending signals to the brain that drive up blood pressure.
Continue reading “How a blast to the kidney could end high blood pressure for good” »
More drugmakers are betting gene therapies will have a big impact on patients and profits, with Pfizer Inc. last month agreeing to collaborate with Paris-based Vivet Therapeutics on a treatment for a rare liver disorder. The U.S. Food and Drug Administration forecasts as many as 20 cell- and gene-therapy approvals each year by 2025. Doubts remain about whether the treatments will sustain their dramatic results, making it difficult to determine their value.
Dozens of revolutionary gene therapies that mend faulty strands of DNA are on their way, bringing the power to eliminate lethal childhood diseases, rare blood disorders and other severe illnesses.
Beneath the excitement about these potential cures lies an important catch: no one knows how much to charge for them.
Continue reading “Gene Therapy Was Hailed as a Revolution. Then Came the Bill” »
Usually, this kind of surgery involves cutting and suturing, which is painful and leaves scars. Now, researchers at Occidental College in Los Angeles and the University of California, Irvine, have reshaped tissue with no incisions or scarring, and minimal recovery time.
It could be useful for cosmetic surgery – such as reshaping a nose or ear – but also for problems such as immobile joints and poor eyesight.
One of the research’s lead investigators, Michael Hill, said in a press release, “We envision this new technique as a low-cost office procedure done under local anesthesia. The whole process would take about five minutes.”
While currently in the process of arranging licensing for their procedure, the researchers are already looking toward using it with other collagen tissue such as tendons, and even corneas for the correction of vision issues. In animal tests, they’ve already had some success with reshaping a cornea using a 3D-printed contact lens painted with electrodes and to which they applied electrical current to soften the cornea. This is especially exciting due to the structure of its collagen fibers. Says Hill during the presentation, “It turns out that in order to remain transparent, the [layers of] collagen fibers are all perfectly aligned.” Molecular surgery allows correction of the cornea without disrupting that required layering.
Scientists at Stanford University say they’ve devised antibodies that block a specific gene related to brain aging — and that it’s giving old mice the cognitive prowess of younger ones.
“The mice became smarter,” senior author Tony Wyss-Coray said in a statement. “Blocking [the gene] CD22 on their microglia restored their cognitive function to the level of younger mice. CD22 is a new target we think can be exploited for treatment of neurodegenerative diseases.”
A fringe group of scientists and tech moguls think they’re closing in on the fountain of youth. Here’s everything you need to know:
What is biohacking? Silicon Valley is built on the idea that technology can optimize, or “hack,” any aspect of our lives — so why not the human life span? Until recently, anyone hawking pills or treatments that promised to restore youthfulness was considered a quack, yet a growing number of “transhumanists” are convinced that, in time, human beings can be transformed through bioengineering, and that aging will be curable just like any other malady.
In light of rapid gains in gene editing, nanotechnology, and robotics, some futurists expect this generation’s biohackers to double their life spans. Aubrey de Grey, a regenerative medicine researcher backed by tech mogul Peter Thiel, insists that someone alive today will live to be 1,000. “It’s extraordinary to me that it’s such an incendiary claim,” de Grey says. Korean physician and financier Joon Yun has offered two $500,000 prizes to anyone who can restore a test animal’s youthful heart rate and extend its lifespan by 50 percent. For humans, the mortality rate at age 20 is 0.001 percent, Yun figures, “so if you could maintain the homeostatic capacity of that age throughout your life, your average life span would be 1,000.”
A team of researchers from Nanjing and Xiamen Universities in China has developed an alternative to using viruses to transport CRISPR-Cas9 gene editing tools into a desired cell—and it involves two types of light. In their paper published in the journal Science Advances, the group describes their new type of carrier and how well it worked with test mice.
CRISPR-Cas9 gene editing tools are a coming revolution in treating genetic conditions, and scientists continue to test their abilities in a variety of applications. One area of study has involved looking for a replacement carrier system—the current approach uses a virus to carry the gene editing tool into a particular cell. Early on, researchers knew that the virus approach was not viable because of possible responses from the immune system, or worse, the threat of initiating tumors. In this new effort, the team in China has come up with an entirely new way to deliver the gene editing tool using two kinds of light.
Their carrier system consists of nanoparticles that are sensitive to low-energy near–infrared radiation (NIR) and that emit UV light. When NIR is shone on the nanoparticles, the light is absorbed and converted to UV light, which is emitted. Inside of a cell, the package is activated by shining NIR onto the skin, where it penetrates into the body and makes its way to the gene editing tool. When the NIR is converted to UV light, it cuts molecules in the carrier package, releasing the gene editing tool to do its work.
Continue reading “A light-based carrier system for CRISPR-Cas9 gene editing” »
